New Insights from Taiki Hakozaki et al. on Gut Microbiota’s Role in NSCLC – IASLC
International Association for the Study of Lung Cancer (IASLC) shared a post on LinkedIn about a paper by Taiki Hakozaki et al. published in the Journal of Thoracic Oncology:
“The role of gut microbiota as a potential biomarker for first-line treatment selection in NSCLC has remained unclear. This biomarker study from the Phase III NIPPON trial by Hakozaki et al. provides new insights into this topic.
Read now.”
Title: Gut Microbiota in Advanced NSCLC Receiving Chemoimmunotherapy: An Ancillary Biomarker Study From the Phase III Trial JCOG2007 (NIPPON)
Authors: Taiki Hakozaki, Kentaro Tanaka, Yoshimasa Shiraishi, Yuta Sekino, Noriko Mitome, Yusuke Okuma, Tomoiki Aiba, Takahiro Utsumi, Junko Tanizaki, Koichi Azuma, Satoshi Hara, Ryo Morita, Seiji Niho, Toshihide Yokoyama, Ryo Toyozawa, Hidehito Horinouchi, Isamu Okamoto, Yukio Hosomi, Yuichiro Ohe
You can read the Full Article in the Journal of Thoracic Oncology.
More posts featuring IASLC.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023